Subsidiary of ApicHope Pharmaceutical Group (300723.SZ) Obtains Registration Certificate for Concentrated Solution of Sodium Valproate for Injection

ApicHope Pharmaceutical Group (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the concentrated solution of sodium butyrate injection. This approval allows the company to sell the specified drug in the domestic market, expanding its product line and categories, and enhancing its competitiveness in the field of chronic disease medications.